No problem speakhim, glad to:
A multitude of clues which tweak my instincts, can't say more than that, but my instincts are often reliable:
The official silence of BIEL - rare in the past, the CEO is silent;
Paul, an IR fellow, advising investors of meeting with FDA;
I do not have an answer re # of shares traded today, but someone (plural) is buying and I have tried to solicit opinions on this from good guys here, but everyone is busy and I am patient;
The occurance of all this seems timely - a few weeks after BIEL raised the issue that the FDA missed something on ALLAY, OR BIEL was less than clear, I don't really care which, as long as it is/was clarified. They involved the correct people, legal counsel obviously wrote the letter to shareholders, Senator Mikulski of Maryland, the Inspector General became involved, Senators are writing response letters and I know Senators,and Congressmen and Mayors, whether sitting or candidates, avoid losers like the plague - there is nothing negative about BIEL's products. No nastiness, only professionalism that something had been missed, normal regulatory process steps;
There is no factual reason for FDA declining anything with regard to PEMF and BIEL's product line, its been around for 30 years, but obviously there is still pioneering going on.....devices are still fairly new to the FDA wheelhouse and a device to replace painkiller drugs? Nonsens!!! But you watch - my prediction is PEMF devices will be out in the main floor area in US drugstores because there are NO ADVERSE SIDE EFFECTS, something I would respectfully suggest puts everyone at the FDA a little on edge;
My first-hand experience with ActiPatch (only) was amazing. It reversed a healing prognosis from an excellent athletic doctor on a badly sprained ankle from a couple of months, because he said a really bad sprain is often worse than a fracture. He was convinced I had broken it till he read the X-rays. To my returning his crutches after a few days and walking easily on it - incredibly reduced swelling and healing - he and I both couldn't believe it!;
Small companies with little money take tiny steps and it seems to me that BIEL has made errors in the regulatory process due to inexperience. Doesn't bother me terribly, but it is frustrating and it just takes longer, while the patent clock ticks;
There are emany other clues, but who really knows what contitutes instincts, and I'm pressed for time. A major clue is I'm in this for the long haul, not to play the long and short swings combined with no one has even suggested it does not work or that there are adverse side-effects and I smile.....
Market Data 
Markets 
AI
